Tepoxalin

DB11466

small molecule vet_approved

Deskripsi

Tepoxalin is a nonsteroidal anti-inflammatory drug approved for veterinary use in the United States and many other countries. It is primarily used to reduce inflammation and relief of pain caused by musculoskeletal disorders such as hip dysplasia and arthritis.

Struktur Molekul 2D

Berat 385.85
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1647 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Tepoxalin.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Tepoxalin.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tepoxalin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tepoxalin.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tepoxalin.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tepoxalin.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Tepoxalin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tepoxalin.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Tepoxalin.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tepoxalin.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Tepoxalin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tepoxalin.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tepoxalin.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Tepoxalin.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tepoxalin.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tepoxalin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Tepoxalin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Tepoxalin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Tepoxalin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tepoxalin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Tepoxalin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tepoxalin.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Tepoxalin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Tepoxalin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tepoxalin.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tepoxalin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Tepoxalin.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tepoxalin.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Tepoxalin.
Cladribine Tepoxalin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Tepoxalin.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Tepoxalin.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Tepoxalin.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Tepoxalin.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Tepoxalin.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Tepoxalin.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Tepoxalin.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Tepoxalin.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Tepoxalin.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Tepoxalin.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Tepoxalin.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Tepoxalin.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Tepoxalin.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Tepoxalin.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Tepoxalin.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Tepoxalin.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Tepoxalin.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Tepoxalin.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Tepoxalin.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Tepoxalin.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Tepoxalin.
Oxaliplatin The risk or severity of nephrotoxicity can be increased when Oxaliplatin is combined with Tepoxalin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Tepoxalin.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Tepoxalin.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Tepoxalin.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Tepoxalin.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Tepoxalin.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Tepoxalin.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Tepoxalin.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Tepoxalin.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Tepoxalin.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tepoxalin.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tepoxalin.
Tretinoin The risk or severity of elevated intracranial pressure can be increased when Tepoxalin is combined with Tretinoin.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Tepoxalin.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Tepoxalin.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Tepoxalin.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Tepoxalin.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Tepoxalin.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Tepoxalin.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Tepoxalin.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Tepoxalin.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Tepoxalin.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Tepoxalin.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Tepoxalin.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Tepoxalin.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Tepoxalin.
Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Tepoxalin.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Tepoxalin.
Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Tepoxalin.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tepoxalin.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Tepoxalin.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Tepoxalin.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Tepoxalin.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Tepoxalin.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Tepoxalin.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Tepoxalin.
Capecitabine Capecitabine may increase the nephrotoxic activities of Tepoxalin.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Tepoxalin.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Tepoxalin.
Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Tepoxalin.
Ifosfamide The risk or severity of adverse effects can be increased when Ifosfamide is combined with Tepoxalin.
Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Tepoxalin.
Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Tepoxalin.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Tepoxalin.
Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Tepoxalin.
Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Tepoxalin.
Dasatinib The risk or severity of adverse effects can be increased when Dasatinib is combined with Tepoxalin.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Tepoxalin.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Tepoxalin.

Target Protein

Interleukin-4 IL4
Polyunsaturated fatty acid 5-lipoxygenase ALOX5

Referensi & Sumber

Artikel (PubMed)
  • PMID: 23802664
    McCarthy RJ: Tepoxalin no longer available commercially. Am J Vet Res. 2013 Jul;74(7):948. doi: 10.2460/ajvr.74.7.948.
  • PMID: 19161461
    De Boever S, Neirinckx E, Baert K, De Backer P, Croubels S: Pharmacokinetics of tepoxalin and its active metabolite in broiler chickens. J Vet Pharmacol Ther. 2009 Feb;32(1):97-100. doi: 10.1111/j.1365-2885.2008.01000.x.
  • PMID: 21348304
    Guo XH, Zhang HW, Tao L, Li YJ, Wang PA, Wang SY, Wang Q, Dong LH, Chang JB: Novel synthetic method and analgesic activity of tepoxalin. Yao Xue Xue Bao. 2010 Oct;45(10):1260-4.
  • PMID: 8707445
    Ritchie DM, Argentieri DC, Aparicio BL, Plante RK, Lau CY, Barbone AG: Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Int J Immunopharmacol. 1995 Oct;17(10):805-12.
  • PMID: 19175721
    Goodman L, Torres B, Punke J, Reynolds L, Speas A, Ellis A, Budsberg S: Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. J Vet Intern Med. 2009 Jan-Feb;23(1):56-62. doi: 10.1111/j.1939-1676.2008.0226.x.
  • PMID: 16343292
    Fusellier M, Desfontis JC, Madec S, Gautier F, Marescaux L, Debailleul M, Gogny M: Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor. J Vet Pharmacol Ther. 2005 Dec;28(6):581-6.
  • PMID: 17718810
    Bosmans T, Gasthuys F, Duchateau L, de Bruin T, Verhoeven G, Polis I: A comparison of tepoxalin-buprenorphine combination and buprenorphine for postoperative analgesia in dogs: a clinical study. J Vet Med A Physiol Pathol Clin Med. 2007 Sep;54(7):364-9.
  • PMID: 7775455
    Tam SS, Lee DH, Wang EY, Munroe DG, Lau CY: Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities. J Biol Chem. 1995 Jun 9;270(23):13948-55.
Menampilkan 8 dari 28 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Zubrin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul